All lobbying filings

GRIDIRON PUBLIC AFFAIRS, LLC

Lobbying for BEAM THERAPEUTICS · Biotech/biopharmaceutical companies

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$10,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing

Bills named in this filing 3

H.R. 7871
MVP Act
H.R. 5187
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing ca…
H.R. 7837
Most Favored Patient Act of 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.